Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $179.56B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: GILD stock price vs EXAS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EXAS's multiple
Needs EXAS P/E.
Implied fair value · at GILD's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
EXACT SCIENCES CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
GILD vs ABBV
AMGEN INC
GILD vs AMGN
BRISTOL MYERS SQUIBB CO
GILD vs BMY
Merck & Co., Inc.
GILD vs MRK
PFIZER INC
GILD vs PFE
REGENERON PHARMACEUTICALS, INC.
GILD vs REGN
Guardant Health, Inc.
GILD vs GH
Natera, Inc.
GILD vs NTRA
NEOGENOMICS INC
GILD vs NEO
OPKO HEALTH, INC.
GILD vs OPK
LABCORP HOLDINGS INC.
GILD vs LH
QUEST DIAGNOSTICS INC
GILD vs DGX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe profitability and return on capital will matter more than top-line growth, then prefer GILD over EXAS because GILD combines 28.9% net margin, 22.3% ROIC, and a 7/9 Piotroski F-Score while EXAS is still loss-making despite faster revenue growth.
GILD trades at a rich but defensible valuation relative to its quality, with a 19.4x P/E and 5.5x P/S supported by strong margins and returns. EXAS cannot be valued on earnings because it has negative net income, so the comparison favors GILD on realized profitability rather than speculative growth.
Supporting Metrics
